Participated · Series C · Mar 2022

Founded in 2014, SJSemi focuses on 12-inch mid-end wafer production and end-to-end wafer-level advanced packaging and testing services, including multi-die integration and chiplet solutions. The company serves smartphones, 5G, high-performance computing, data centers, automotive and other electronics markets. SJSemi has invested heavily in R&D, notably debuting a 3x reticle TSV interposer technology in May 2024 and pursuing ultra-high density 3D multi-die integration. According to Yole and CIC Insight Consulting, SJSemi saw top revenue growth among global OSATs in 2023, and ranks No.1 in mainland China for 12-inch bumping, 12-inch WLCSP market share and wafer testing/chip probing revenue. As of 2024 it is the only provider in mainland China capable of mass-producing silicon-based 2.5D packaging solutions. The company is progressing an IPO application and is expanding its one-stop multi-die integration offerings via continued investment. SJ Semiconductor (SJSemi) is a pioneer of 12-inch MEOL foundry services in China, known for high-density bumping, WLCSP and testing. It offers advanced packaging using bumping and RDL technologies, and provides silicon interposer, fan-out wafer and substrate solutions. The company serves IC customers domestically and overseas across smartphones, networking, data center, AI and automotive markets. SJSemi leverages front-end fab management and quality systems to deliver high-performance advanced packaging. Financially, the company has completed a $340M Series C+ tranche that pushes total capital raised above $1 billion and valuation close to $2 billion. Management has indicated it will remain open to additional US dollar funding and will close an RMB tranche after required ODI approvals. SJSemi is a Jiangyin, China-based MEOL foundry founded in August 2014. The company provides Middle-End-Of-Line manufacturing and testing services and develops advanced bumping and 3D Multi-Die Integration technology and solutions. Its core capabilities focus on advanced bumping and 3D multi-die integration for semiconductor packaging. SJSemi closed a $300M Series C that brings its total equity raised to $630M, strengthening its balance sheet. The company says the funding will enable it to continue growing according to its business plan and strengthen its position in advanced packaging. Backers on the round included CMBI, CICC Capital, Oriza Rivertown, Oriza Hua Capital, Walden CEL, CCB PE, CCB Trust, Growth, Country Garden Venture, HTPE, SCGC, CITIC Securities, GP Capital and others.

Participated · Series C · Mar 2022

DataGrand is a Shanghai-based AI and RPA vendor whose platform combines Robotic Process Automation (RPA) with Intelligent Document Processing (IDP) to enable smart office automation. Its system supports scenarios such as contract review, data search and recommendation, automatic reporting and text analysis. Core technologies and solutions include natural language processing (NLP), optical character recognition (OCR), knowledge graphs, intelligent recommendations and hyperautomation. Founded in 2015, the company has deployed its offerings for many Fortune 500 companies’ smart office use cases. DataGrand completed a $90M Series C financing to bolster its market position. It intends to use the proceeds to strengthen its lead in Intelligent RPA and accelerate technical innovation and industrial application of its core products and solutions. DataGrand is a Chinese AI company founded in 2015 and led by CEO Dr. Chen Yunwen. It develops and applies natural language processing (NLP), optical character recognition (OCR), knowledge-graph and RPA technologies to deliver text automation solutions such as documentation review, intelligent recommendation, intelligent search and knowledge mapping. The company notes its solution does not use Microsoft’s underlying development frameworks and is deployed across dozens of vertical industries and by more than 100 enterprises. DataGrand has established strategic partnerships with Microsoft, Sogou and China Ping An Group. Customers include China UnionPay, Shenzhen Stock Exchange, HSBC, Deloitte, China Mobile, Huawei, Haier and Decathlon. It closed a CNY 270m (USD 38m) B+ funding round and intends to use the proceeds to scale up its business.

Participated · Series A · Feb 2022

Hanbang Technology focuses on the research, production, and application of metal (SLM) 3D printing equipment and supplies high‑quality, full‑service 3D printing technical solutions. The company emphasizes intelligent, automated, and digital approaches to deliver enterprise‑level offerings. Its solutions combine “intelligent production lines + mass manufacturing + industrial smart IoT” to provide integrated metal 3D printing capabilities. Hanbang positions itself to offer more efficient and flexible cooperation models for customers and to support batch manufacturing. Recently the company completed a new financing round totaling several hundred million yuan, indicating fresh capital to support its operations and growth. Yunxiu Capital served as exclusive financial adviser on the deal.

Participated · Series F · Aug 2021

Yuanxin Technology builds a digital healthcare platform that connects doctors, hospitals, pharmaceutical companies, insurers and patients via services including Miaoshou Doctor, Yuanxin Pharmacy and Yuanxin Huibao. It provides in-hospital and out-of-hospital integrated diagnosis and treatment solutions, one-stop pharmacy and hospitalization payment, digital-driven marketing and patient rehabilitation support for pharmaceutical companies, and full-stack insurance operation solutions. After this financing, the company plans to expand its service network for discharged patients, customize post-visit disease course management for multi-disease patients, and accelerate construction of a digitized hospital network and a full-cycle patient portal. Yuanxin also intends to further develop multi-disease and multi-form health insurance products and build digital infrastructure—IT and data systems—that connect patients, doctors, hospitals, pharmaceutical companies, and insurers. Founded in 2015, the company says it has taken a leading role in the “hospital-medication-insurance-patient” model and has maintained sustained rapid growth and top industry positioning. The company completed over ¥1.5 billion in Series F financing, which will support its expansion and digitalization plans. Beijing Yuanxin Technology Co., Ltd is a specialist in digital healthcare and chain pharmacies, operating both digital health services and pharmacy chains. The company focuses on integrating digital healthcare solutions with traditional pharmacy operations. It is identified by its Beijing affiliation in the company name. Recently it completed a major financing round, indicating investor confidence in its business model. No operating metrics or revenue figures were disclosed in the article. Future plans were not specified in the article. Beijing Yuanxin Technology Company Limited, also known as Miaoshou Doctor, is described in reporting as a digital/internet health service provider. The company operates in online health services under the Miaoshou Doctor name. According to the coverage, it has secured an aggregate of 600 million yuan, roughly $85 million. That amount was raised in a Series D1 round. Investors named in the reporting include Sequoia and Qiming, alongside other unspecified participants. The article does not disclose additional operating metrics, valuation, or founding-year information. Miaoshou Doctor is a China-based company reported in DealStreetAsia's roundup of Chinese funding news. The article states the company completed a 500 million-yuan Series C+ financing (about $72.77 million). The report identifies Starquest Capital as the lead investor for the round. The article does not provide details on Miaoshou Doctor’s core product, operating metrics, or future plans. This funding announcement was reported alongside other China tech deals, including SenseTime’s investment in WeRide.

Participated · Series F · Aug 2021

Yuanxin Technology operates a multi‑business healthcare matrix (including Miaoshou Doctor, Yuanxin Pharmacy, Yuanxin HuiBao and Yuanxin Medical Technology) that links patients, doctors, hospitals, pharma and insurers through digital and offline services. The company focuses on building an out‑of‑hospital disease‑management network and an in‑hospital digital smart service network to provide integrated, full‑cycle care and payment solutions. It offers digital marketing, sales, R&D and patient‑management solutions for pharma, one‑stop services for doctors (education, multi‑site practice, patient management) and full‑stack operational solutions for insurers. Future plans described in the articles include expanding patient out‑of‑hospital service networks, accelerating construction of a digital hospital network, developing multi‑disease commercial health insurance products, and building an IT and data infrastructure that connects stakeholders. Founded in 2015 and headquartered in Beijing, the company positions itself as a market leader capturing synergies across medical, pharma and insurance ecosystems. The articles highlight a diversified top‑tier investor base and continued strategic capital support as validation of its growth potential.